This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics